权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Phenotype and Genotype of Autosomal Dominant Alzheimer's Disease in Jalisco, Mexico

墨西哥哈利斯科州常染色体显性阿尔茨海默病的表型和基因型

基本信息

批准号：
10261579
负责人：
JOHN M RINGMAN
金额：
$ 65.8万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-15 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10261579
关键词：
Adult Advocacy Affect Age Age of Onset Alzheimer&apos s Disease Amyloid Beta A4 Precursor Protein C9ORF72 CSF1R gene California Clinic Clinical Clinical Research Clinical Trials Clinical assessments Cognitive Collaborations Colombia Data Set Development Disease Elements Ethics Evaluation Extended Family Family Founder Effect Functional disorder Funding Future Gender Genes Genetic Genetic Counseling Genetic Predisposition to Disease Genetic Screening Genetic study Genotype Goals Impaired cognition Infrastructure Inherited International Intervention Leg Measures Medical Genetics Mentorship Mexican Mexico Mutation Neurodegenerative Disorders Neurologic Neuropsychology Onset of illness Pathogenicity Patient Care Performance Persons Phase Phenotype Population PrP gene Presenile Alzheimer Dementia Prevention Procedures Protocols documentation Reporting Research Research Infrastructure Research Personnel Resources Risk Spastic Paraparesis Standardization System Technology Testing Training United States National Institutes of Health Universities Work autosomal dominant Alzheimer&apos s disease base behavioral phenotyping cognitive testing cohort disease phenotype disease-causing mutation evidence base exome sequencing genetic testing genetic variant improved mutation carrier presenilin-1 presenilin-2 presymptomatic testing prospective research clinical testing research study standardize measure

项目摘要

The study of persons with or at-risk for genetically-determined autosomal dominant Alzheimer’s disease (ADAD) due to mutations in the PSEN and APP genes has made tremendous contributions to our understanding of AD in general. As the future development of AD in persons inheriting ADAD mutations can be reliably predicted, one can define the disease phenotype and changes occurring during the presymptomatic phase of the disease with great sensitivity, enabling the evaluation of other factors influencing disease course (e.g. modifying genes, effects of putative disease-modifying interventions). Such research is facilitated by the identification of large families sharing the same genetic predisposition, an approach that has been best implemented in an extended family in Colombia with a common mutation in PSEN1 (E280A). A similar founder effect for a distinct mutation in PSEN1 (A431E) and another large family with a different ADAD-causing mutation in APP (V717I) has been identified in the State of Jalisco in Mexico but to date these families have been understudied. The goal of the current application is to facilitate the performance of clinical studies of this population by investigators in Jalisco. This will be achieved through the following specific aims: Specific Aim #1) To characterize and follow persons with and at-risk for ADAD in Jalisco by harmonizing measures between the Centro de Investigación Biomédica de Occidente Genetics clinic in Guadalajara, the University of Guadalajara Polyclinic in Tepatitlan, and the USC Alzheimer’s Disease Research Center. By providing gene-sequencing technology and training, we will also enable the genetic characterization of this population. Specific Aim #2) To perform studies to identify genes that affect the age of disease onset and the presence of leg stiffness in ADAD. Specific Aim #3) To improve the ability of clinicians and researchers in Jalisco to deliver presymptomatic genetic counseling for persons at-risk for ADAD, thus optimizing autonomy with regards to research participation. This project will improve our understanding of the pathophysiology of ADAD and lay the groundwork for future studies of this informative population in Mexico.

遗传决定的常染色体显性阿尔茨海默氏症患者或高危人群的研究